市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Invivyd, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
-0.5
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -2.0 |
| 平均 | -0.50 |
|
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 41.18% |
| 机构持股比例 | 66.10% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Bvf Inc/Il | 30 Jun 2026 | 28,165,000 |
| Maverick Capital Ltd | 30 Jun 2026 | 18,970,913 |
| Perceptive Advisors Llc | 30 Jun 2026 | 18,490,636 |
| M28 Capital Management Lp | 30 Jun 2026 | 9,248,250 |
| Saturn V Capital Management Lp | 30 Jun 2026 | 8,392,288 |
| Soleus Capital Management, L.P. | 30 Jun 2026 | 7,708,727 |
| Siren, L.L.C. | 30 Jun 2026 | 5,000,000 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合